The Future of Cryonics: Tomorrow.Bio's Bold Leap into the U.S. Market
May 23, 2025, 11:44 pm
In a world where death is often seen as the final chapter, a Berlin-based startup is rewriting the narrative. Tomorrow.Bio, Europe’s first cryonics lab, has just secured €5 million in funding to expand its revolutionary services into the United States. This is not just a business venture; it’s a bold step into the realm of life and death, a leap into the unknown.
Cryonics is a concept that sounds like science fiction. Imagine being preserved at ultra-low temperatures, frozen in time, with the hope of revival when medical technology advances. Tomorrow.Bio offers this very service. Founded in 2020 by Dr. Emil Kendziorra and Fernando Azevedo Pinheiro, the company aims to provide long-term cryopreservation for individuals who choose to be stored after legal death. It’s a radical idea, but for many, it represents a flicker of hope in the face of terminal illness.
The recent funding round was co-led by Blast.Club and Truventuro, two investors with a keen eye for innovative ventures. Their support is a testament to the potential they see in Tomorrow.Bio’s mission. The company has already cryopreserved 20 individuals and 10 pets, with over 800 more signed up. The total contract value has surpassed €160 million, indicating a growing interest in this unconventional approach to life extension.
Cryopreservation is a meticulous process. It involves cooling the body to minus 196°C, halting all biological activity. Tomorrow.Bio employs a fleet of cryo-ambulances, equipped to initiate the cooling process immediately after legal pronouncement of death. This is where the company’s “standby teams” come into play. Based in Berlin and Zurich, these teams perform chest compressions, supply oxygen, and begin the cooling process en route to the storage facility in Switzerland. It’s a race against time, a delicate dance between life and death.
Once at the facility, patients are preserved in high-tech dewars, vacuum-insulated containers filled with liquid nitrogen. These containers require no electricity, ensuring that the preservation process remains uninterrupted. The collaboration with the European Biostasis Foundation (EBF) enhances Tomorrow.Bio’s credibility, positioning it as a leader in the field of cryonics.
The founders, Kendziorra and Pinheiro, are not new to the startup scene. Both have a background in technology and entrepreneurship, having founded and exited tech companies before venturing into cryonics. Their experience is invaluable as they navigate the complexities of this emerging industry. Kendziorra’s background as a cancer researcher fuels his passion for finding solutions to terminal illnesses. The slow progress in curing diseases like cancer pushed him to explore alternative avenues, leading to the birth of Tomorrow.Bio.
As Tomorrow.Bio sets its sights on the U.S. market, it plans to establish partner medical teams in at least three states: New York, California, and Florida. This expansion is not just about geographical reach; it’s about making cryonics accessible to a broader audience. The U.S. has a rich history of innovation and a population that is increasingly open to exploring unconventional medical solutions. Tomorrow.Bio aims to tap into this mindset, offering a service that challenges traditional views on life and death.
The investment from Blast.Club and Truventuro is not merely financial; it’s a vote of confidence in Tomorrow.Bio’s vision. The founders believe that advancements in medical technology will one day allow for the revival of cryopreserved individuals. This belief is what drives their relentless pursuit of excellence in preservation techniques. The funds will be used to enhance research and development, ensuring that Tomorrow.Bio remains at the forefront of cryonics technology.
Critics may argue that cryonics is a gamble, a leap of faith into the unknown. However, for many, it represents a chance to defy the finality of death. The idea of being preserved until a cure is found is a powerful motivator. It speaks to the human desire for survival, for a second chance at life. Tomorrow.Bio is not just selling a service; it’s offering hope.
As the company prepares for its U.S. expansion, it faces challenges. The regulatory landscape surrounding cryonics is complex, and public perception varies widely. Some view it as a miracle, while others see it as a folly. Tomorrow.Bio must navigate these waters carefully, educating the public and building trust in its methods.
In a world where medical advancements are rapidly evolving, Tomorrow.Bio stands at the intersection of science and hope. The company’s mission is ambitious, but so is the potential impact. If successful, it could redefine our understanding of life, death, and what lies beyond.
Tomorrow.Bio is not just a cryonics lab; it’s a beacon for those who dare to dream of a future where death is not the end. As they prepare to launch their services in the U.S., the world watches with bated breath. Will they succeed in their quest to change the narrative of life and death? Only time will tell. But for now, they are pushing the boundaries of what is possible, one frozen heartbeat at a time.
Cryonics is a concept that sounds like science fiction. Imagine being preserved at ultra-low temperatures, frozen in time, with the hope of revival when medical technology advances. Tomorrow.Bio offers this very service. Founded in 2020 by Dr. Emil Kendziorra and Fernando Azevedo Pinheiro, the company aims to provide long-term cryopreservation for individuals who choose to be stored after legal death. It’s a radical idea, but for many, it represents a flicker of hope in the face of terminal illness.
The recent funding round was co-led by Blast.Club and Truventuro, two investors with a keen eye for innovative ventures. Their support is a testament to the potential they see in Tomorrow.Bio’s mission. The company has already cryopreserved 20 individuals and 10 pets, with over 800 more signed up. The total contract value has surpassed €160 million, indicating a growing interest in this unconventional approach to life extension.
Cryopreservation is a meticulous process. It involves cooling the body to minus 196°C, halting all biological activity. Tomorrow.Bio employs a fleet of cryo-ambulances, equipped to initiate the cooling process immediately after legal pronouncement of death. This is where the company’s “standby teams” come into play. Based in Berlin and Zurich, these teams perform chest compressions, supply oxygen, and begin the cooling process en route to the storage facility in Switzerland. It’s a race against time, a delicate dance between life and death.
Once at the facility, patients are preserved in high-tech dewars, vacuum-insulated containers filled with liquid nitrogen. These containers require no electricity, ensuring that the preservation process remains uninterrupted. The collaboration with the European Biostasis Foundation (EBF) enhances Tomorrow.Bio’s credibility, positioning it as a leader in the field of cryonics.
The founders, Kendziorra and Pinheiro, are not new to the startup scene. Both have a background in technology and entrepreneurship, having founded and exited tech companies before venturing into cryonics. Their experience is invaluable as they navigate the complexities of this emerging industry. Kendziorra’s background as a cancer researcher fuels his passion for finding solutions to terminal illnesses. The slow progress in curing diseases like cancer pushed him to explore alternative avenues, leading to the birth of Tomorrow.Bio.
As Tomorrow.Bio sets its sights on the U.S. market, it plans to establish partner medical teams in at least three states: New York, California, and Florida. This expansion is not just about geographical reach; it’s about making cryonics accessible to a broader audience. The U.S. has a rich history of innovation and a population that is increasingly open to exploring unconventional medical solutions. Tomorrow.Bio aims to tap into this mindset, offering a service that challenges traditional views on life and death.
The investment from Blast.Club and Truventuro is not merely financial; it’s a vote of confidence in Tomorrow.Bio’s vision. The founders believe that advancements in medical technology will one day allow for the revival of cryopreserved individuals. This belief is what drives their relentless pursuit of excellence in preservation techniques. The funds will be used to enhance research and development, ensuring that Tomorrow.Bio remains at the forefront of cryonics technology.
Critics may argue that cryonics is a gamble, a leap of faith into the unknown. However, for many, it represents a chance to defy the finality of death. The idea of being preserved until a cure is found is a powerful motivator. It speaks to the human desire for survival, for a second chance at life. Tomorrow.Bio is not just selling a service; it’s offering hope.
As the company prepares for its U.S. expansion, it faces challenges. The regulatory landscape surrounding cryonics is complex, and public perception varies widely. Some view it as a miracle, while others see it as a folly. Tomorrow.Bio must navigate these waters carefully, educating the public and building trust in its methods.
In a world where medical advancements are rapidly evolving, Tomorrow.Bio stands at the intersection of science and hope. The company’s mission is ambitious, but so is the potential impact. If successful, it could redefine our understanding of life, death, and what lies beyond.
Tomorrow.Bio is not just a cryonics lab; it’s a beacon for those who dare to dream of a future where death is not the end. As they prepare to launch their services in the U.S., the world watches with bated breath. Will they succeed in their quest to change the narrative of life and death? Only time will tell. But for now, they are pushing the boundaries of what is possible, one frozen heartbeat at a time.